var data={"title":"Roflumilast: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Roflumilast: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/444630?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=roflumilast-patient-drug-information\" class=\"drug drug_patient\">see &quot;Roflumilast: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12918639\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Daliresp</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11450895\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Daxas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460288\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Phosphodiesterase-4 Enzyme Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460378\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>COPD:</b> Oral: 250 mcg once daily for 4 weeks, followed by 500 mcg once daily. <b>Note:</b> An initial dose of 250 mcg once daily is recommended for the first 4 weeks of treatment in an attempt to improve tolerability. However, this is not considered a therapeutic dose and the effect of this approach on long-term tolerability is uncertain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460379\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460380\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460381\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate to severe impairment (Child-Pugh class B or C): Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12915805\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Daliresp: 250 mcg, 500 mcg [contains corn starch]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460286\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460409\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Daxas: 500 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13727205\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022522s006lbl.pdf#page=16&amp;token=m+giqyXXKmnJnVxeJxF+PPnMtb4Iw7nKjOn8H5y82xB56ovMGHCjAy2tcGC4m98QCkA8t+g9w6N7bcWDx7Le7IFWkVhzyv8k5h7fwsevtJAXMRdIYiS4PSYtcQzsbF3p&amp;TOPIC_ID=16465\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022522s006lbl.pdf#page=16</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460406\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460289\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>COPD:</b> To reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for the relief of acute bronchospasm</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460344\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (4%), dizziness (2%), insomnia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (5% to 10% of body weight: 8% to 20%; &gt;10% loss: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (10%), nausea (5%), decreased appetite (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;2%, postmarketing, and/or case reports: Abdominal pain, anemia, anxiety, arthralgia, arthritis, atrial fibrillation, constipation, depression, dysgeusia, dyspepsia, epistaxis, fatigue, gastritis, gastroesophageal reflux disease, gynecomastia, hematochezia, hypersensitivity, hypersensitivity reaction (including angioedema, urticaria, and rash), increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum AST, limb pain, lung carcinoma, malaise, muscle spasm, myalgia, myasthenia, nervousness, pancreatitis, paresthesia, prostate carcinoma, renal failure, respiratory tract infection, rhinitis, sinusitis, suicidal ideation, suicidal tendencies, suicide, supraventricular cardiac arrhythmia, tremor, urinary tract infection, vertigo, vomiting, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460292\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate to severe hepatic impairment (Child-Pugh class B or C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to roflumilast or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460293\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric: Neuropsychiatric effects (eg, anxiety, depression, insomnia) have been reported with use; rarely, suicidal behavior/ideation and completed suicide were reported. Assess risk versus benefits before prescribing in patients with a history of depression with suicidal behavior/ideations; instruct patients/caregivers to report psychiatric symptoms and consider discontinuation of therapy in such patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight loss: Weight loss has occurred; monitor weight regularly. If unexplained or significant weight loss occurs, discontinuation should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild impairment (systemic exposure may be increased); use in moderate to severe impairment is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated for relieving acute bronchospasm.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300013\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562394\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16465&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase serum concentrations of the active metabolite(s) of Roflumilast. Cimetidine may increase the serum concentration of Roflumilast.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Roflumilast.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Roflumilast. Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase serum concentrations of the active metabolite(s) of Roflumilast. FluvoxaMINE may increase the serum concentration of Roflumilast.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: Roflumilast may enhance the immunosuppressive effect of Immunosuppressants. <b> Exceptions: </b>Beclomethasone (Oral Inhalation); Cytarabine (Liposomal); Fluticasone (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Roflumilast. Management: Roflumilast U.S. prescribing information recommends against combining rifampin with roflumilast.  The Canadian product monograph makes no such recommendation but notes that rifampin may reduce roflumilast therapeutic effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Roflumilast may enhance the hypotensive effect of Riociguat.  Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460290\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460291\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if roflumilast is present in breast milk; however, excretion into human breast milk is likely. Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460408\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests; weight (regularly during therapy); new or worsening insomnia, anxiety, depression, suicidal thoughts, or other mood changes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460404\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Roflumilast and its active N-oxide metabolite selectively inhibit phosphodiesterase-4 (PDE4) leading to an accumulation of cyclic AMP (cAMP) within inflammatory and structural cells important in the pathogenesis of COPD. Anti-inflammatory effects include suppression of cytokine release and inhibition of lung infiltration by neutrophils and other leukocytes. Pulmonary remodeling and mucociliary malfunction are also attenuated. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11460367\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 2.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99%; N-oxide metabolite: 97%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 and CYP1A2 to active N-oxide metabolite; also undergoes conjugation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 17 hours; N-oxide metabolite: 30 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: ~1 hour (delayed by food); N-oxide metabolite: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~70% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322885\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Daliresp Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (20): $280.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg (30): $420.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13276710\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adair (BD);</li>\n      <li>Daksas (UA);</li>\n      <li>Daliresp (BB, CZ, EE, HR, IE, IL, MT, TR);</li>\n      <li>Daxas (AE, AR, AT, BR, CH, CO, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, ID, IE, IS, KR, KW, LB, LT, LU, MT, MY, NL, NO, PH, PL, PT, QA, RO, SA, SE, SI, SK, TH);</li>\n      <li>Daxxas (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Libertek (CZ, ES, IE, MT);</li>\n      <li>Lumast (BD);</li>\n      <li>Roflast (BD);</li>\n      <li>Roxair (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Calverley PM, Rabe KF, Goehring UM, et al, &ldquo;Roflumilast in Symptomatic Chronic Obstructive Pulmonary Disease: Two Randomised Clinical Trials,&rdquo; <i>Lancet</i>, 2009, 374(9691):685-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/roflumilast-drug-information/abstract-text/19716960/pubmed\" target=\"_blank\" id=\"19716960\">19716960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chong J, Poole P, Leung B, et al, &quot;Phosphodiesterase 4 Inhibitors for Chronic Obstructive Pulmonary Disease,&quot; <i>Cochrane Database Syst Rev</i>, 2011, 5:CD002309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/roflumilast-drug-information/abstract-text/21563134/pubmed\" target=\"_blank\" id=\"21563134\">21563134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daliresp (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daxas (roflumilast) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herbert C, Hettiaratchi A, Webb DC, et al, &ldquo;Suppression of Cytokine Expression by Roflumilast and Dexamethasone in a Model of Chronic Asthma,&rdquo; <i>Clin Exp Allergy</i>, 2008, 38(5):847-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/roflumilast-drug-information/abstract-text/18307529/pubmed\" target=\"_blank\" id=\"18307529\">18307529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. <i>Lancet</i>. 2015;385(9971):857-866.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/roflumilast-drug-information/abstract-text/25684586/pubmed\" target=\"_blank\" id=\"25684586\">25684586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rennard SI, Calverley PM, Goehring UM, et al, &quot;Reduction of Exacerbations by the PDE4 Inhibitor Roflumilast -- The Importance of Defining Different Subsets of Patients With COPD,&quot; <i>Respir Res</i>, 2011, 12:18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/roflumilast-drug-information/abstract-text/21272339/pubmed\" target=\"_blank\" id=\"21272339\">21272339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sabatini F, Petecchia L, Boero S, et al, &ldquo;A Phosphodiesterase 4 Inhibitor, Roflumilast N-Oxide, Inhibits Human Lung Fibroblast Functions <i>in vitro</i>,&rdquo; <i>Pulm Pharmacol Ther</i>, 2010, 23(4):283-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/roflumilast-drug-information/abstract-text/20226872/pubmed\" target=\"_blank\" id=\"20226872\">20226872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanz MJ, Cortijo J, Taha MA, et al, &ldquo;Roflumilast Inhibits Leukocyte-Endothelial Cell Interactions, Expression of Adhesion Molecules and Microvascular Permeability,&rdquo; <i>Br J Pharmacol</i>, 2007, 152(4):481-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/roflumilast-drug-information/abstract-text/17704822/pubmed\" target=\"_blank\" id=\"17704822\">17704822</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16465 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F12918639\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11450895\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F11460288\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F11460378\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F11460379\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F11460380\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F11460381\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F12915805\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F11460286\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F11460409\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F13727205\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11460406\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F11460289\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11460344\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11460292\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11460293\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300013\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11562394\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11460290\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11460291\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11460408\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11460404\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11460367\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322885\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13276710\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16465|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=roflumilast-patient-drug-information\" class=\"drug drug_patient\">Roflumilast: Patient drug information</a></li></ul></div></div>","javascript":null}